Oncology
Follicular Thyroid Carcinoma
4
Pipeline Programs↗
0
Active Trials↗
4
Companies Involved↗
Follicular Thyroid Carcinoma is an early-stage landscape with 4 programs across 4 companies. The most active players are Bristol-Myers Squibb, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Teva. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 22
Phase 3
No programs
Analysis
Trial Status
1
clinical trials
Completed1 · 100%
Clinical Trials
Trial Activity
REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
Completed·—·Phase 2·NCT00287287·25 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)